Filter By Category
Archives
Share on -
AVASIMIBE
Generic Name: AVASIMIBE
ABSTRACT -
Avasimibe is an investigational small-molecule acyl-CoA:cholesterol acyltransferase/SOAT inhibitor studied for lipid metabolism and oncology-related research. Its molecular formula is C₂₉H₄₃NO₄S. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved public dosing regimen is established for routine clinical use unless specifically authorized in a local label.
- Clinical-study dosing, when applicable, is protocol-specific and must not be copied into routine practice.
- Do not administer outside an authorized clinical trial, compassionate-use pathway, or approved product labeling.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Gastrointestinal upset, nausea, diarrhea, or abdominal discomfort
- Headache, fatigue, dizziness, or nonspecific malaise
- Changes in lipid parameters or liver enzymes may occur
- Rash or hypersensitivity symptoms are possible
- Long-term clinical safety is not established for routine use
ALLERGIC REACTIONS -
Hypersensitivity to Avasimibe or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avasimibe should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avasimibe may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Lipid-lowering medicines and hepatotoxic agents require review.
- Medicines metabolized by hepatic enzymes may complicate trial interpretation.
- Fat-soluble vitamin or lipid-related therapies should be discussed with investigators.
- Patients should report all medicines, herbal products, and supplements.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor liver enzymes and lipid-related laboratory parameters as required.
- Use caution in significant hepatic disease.
- Do not use for self-treatment of cholesterol or cancer.
- Pregnancy and lactation safety are not established.
WARNINGS –
- Investigational status: safety and effectiveness for routine use may not be established.
- Serious or unexpected adverse events must be managed under protocol and reported promptly.
- Use only by personnel trained for the relevant formulation and administration route.
- Keep out of reach of children.
Share on -
. Developed by